SAN DIEGO, Feb. 29, 2016 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, today
announced the appointment of Sharron Gargosky, PhD, as Head of
Clinical Development and Operations.
"Dr. Gargosky's deep expertise in clinical operations and
development will significantly contribute to the strength of
OncoSec's management team to move our clinical programs forward,
prioritize our product development strategy, and identify
opportunities to leverage ImmunoPulse™ to address a significant
unmet medical need in oncology," said Punit
Dhillon, President and CEO of OncoSec. "We're excited for
Dr. Gargosky to apply her unique background and expertise as a
consultant to advance our clinical programs towards
commercialization."
Dr. Gargosky has over 20 years of experience in clinical
development and operations in the field of pharmaceutical and
biologic development having managed global programs from early
research phase through the U.S. Food & Drug Administration
(FDA) approval process. Recently, Dr. Gargosky was the Chief
Technical and Operations Officer at Prima Biomed, Ltd., where she
led the immuno-oncology program in ovarian and pancreatic cancer
overseeing international manufacturing, regulatory approvals, and
clinical execution. Prior to Prima Biomed, Dr. Gargosky served in
positions of increasing clinical and scientific responsibility at
biopharmaceutical companies including Pharmacia, Medicis, and
Hyperion Therapeutics. In her career, she was involved in small
molecule development attaining orphan drug approvals in rare
diseases. Dr. Gargosky received her PhD from the University of
Adelaide, Australia and completed
her postdoctoral fellowship at Stanford
University.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in Phase II development for several indications, including
metastatic melanoma, squamous cell carcinoma of the head and neck,
and triple-negative breast cancer. In addition to ImmunoPulse™
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse™ platform. For
more information, please visit www.oncosec.com.
Contact
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-appoints-sharron-gargosky-phd-as-head-of-clinical-development-and-operations-300227456.html
SOURCE OncoSec Medical Incorporated